Relative adverse reactions for predicting prognosis of ≥5 cm unresectable hepatocellular carcinoma after treated with drug-eluting beads TACE combined with low-dose apatinib
10.13929/j.issn.1672-8475.2024.12.004
- VernacularTitle:相关不良反应预测药物洗脱微球TACE联合低剂量阿帕替尼治疗≥5 cm不可切除肝细胞癌预后
- Author:
Cheng YE
1
;
Xiaoxu ZHU
;
Jianan WANG
;
Ying XIN
;
Cheng XING
;
Xianliang ZHANG
;
Xin LI
;
Xuhua DUAN
;
Xiaoming WANG
Author Information
1. 周口市中心医院介入科,河南周口 466000;中国医科大学附属盛京医院放射科,辽宁沈阳 110004
- Publication Type:Journal Article
- Keywords:
liver neoplasms;
chemoembolization,therapeutic;
apatinib;
prognosis
- From:
Chinese Journal of Interventional Imaging and Therapy
2024;21(12):742-746
- CountryChina
- Language:Chinese
-
Abstract:
Objective To observe the value of relative adverse reactions for predicting prognosis of ≥5 cm unresectable hepatocellular carcinoma(HCC)after treated with drug-eluting beads TACE(DEB-TACE)combined with low-dose apatinib.Methods Totally 172 patients with unresectable HCC≥5 cm who underwent DEB-TACE combined with low-dose apatinib.Apatinib-related adverse reactions were recorded and graded according to common terminology criteria for adverse events(CTCAE).Multivariate Cox regression model was performed to screen independent impact factors of apatinib-related adverse reactions for predicting survival time of patients after DEB-TACE combined with low-dose apatinib.Results Among 172 cases,apatinib-related adverse reactions included hand-foot syndrome and hypertension in each 147 cases(147/172,85.47％),loss of appetite in 91 cases(91/172,52.91％),diarrhea in 81 cases(81/172,47.09％),fatigue in 75 cases(75/172,43.60％),rashes in 38 cases(38/172,22.09％),oral mucositis in 20 cases(20/172,11.63％)and dysphonia in 18 cases(18/172,10.47％).After correction of baseline data,multivariate Cox regression model showed that grade 1-2 hand-foot syndrome and grade 2 oral mucocitis were all independent factors for predicting survival time after DEB-TACE combined with low-dose apatinib of unresectable HCC≥5 cm(all P＜0.05).Conclusion After DEB-TACE combined with low dose apatinib,patients with unresectable HCC≥5 cm who occurred grade CTCAE 1-2 hand-foot syndrome and grade 2 oral mucositis had better prognosis.
